Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Lack of safe prescribing for vulnerable Scottish patients

Scottish patients vulnerable to adverse drug reactions (ADRs) are being prescribed medicine combinations likely to result in admission to hospital, University of Dundee researchers have warned.

In a study of more than 1.76 million patients from 315 Scottish GP practices, 139,000 were found to be vulnerable to ADRs, of whom 19,308 were found to have at least one high-risk item on their prescriptions.

While not all high-risk prescribing was inappropriate, the study, published in the BMJ, showed "existing activity to improve prescribing is insufficiently focused on safety", the authors from the University of Dundee concluded.

Common problems included 50 per cent of patients aged over 75 prescribed an NSAID without gastroprotection, with one in 10 patients with heart failure also prescribed NSAIDs.

Other issues raised included the lack of a weekly dose with methotrexate, or methotrexate 2.5mg and 10mg being co-prescribed; and antiplatelets or a high-risk antibiotic being prescribed with warfarin.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD014179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel